Regulatory News: MaaT Pharma (EURONEXT: MAAT the "Company"), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving
Data describe rapid, safe and robust microbiome engraftment1 of MaaT033 in the gut of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome undergoing intensive chemotherapy
Data describe rapid, safe and robust microbiome engraftment1 of MaaT033 in the gut of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome undergoing intensive chemotherapy and support the selection of a recommended dose for further developmentMaaT033 is an orally-administered high-richness, hi.
As of March 31, 2022, cash and cash equivalents of positions were EUR 41.1 million1 Revenues of EUR 0.3 million1 in Q1 2022 Regulatory News: MaaT Pharma (EURONEXT: MAAT the "Company")
MaaT Pharma Reports Cash and Revenues for First Quarter 2022 pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.